Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being

Published
03 March 2015
By
Liz Highleyman
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced liver

Published
03 March 2015
By
Liz Highleyman
Delay HCV Tx and Watch Patients Die

Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.

Published
02 March 2015
From
MedPage Today
Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines

An influential advisory panel of doctors and health experts will for the first time address the cost-effectiveness of pricey hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines.

Published
02 March 2015
From
Bloomberg
Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection

A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis

Published
27 February 2015
By
Liz Highleyman
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

Following a request from NHS England and consultation with stakeholders, the period during which NHS England has to comply with the recommendations for sofosbuvir is extended to 31 July 2015. The period during which NHS England has to comply with the recommendations for simeprevir has not been extended.

Published
26 February 2015
From
NICE press release
New hepatitis C treatments highly effective for HIV/HCV coinfected people

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

Published
26 February 2015
From
HIVandHepatitis.com
Sexual Transmission of HCV in Gay Men Should Not Be a PrEP Deterrent, Say Advocates

After two men on pre-exposure prophylaxis (PrEP) at the Kaiser Permanente San Francisco Medical Center tested positive for the hepatitis C virus (HCV), clinicians at the center penned a letter to the editor of the journal Clinical Infectious Diseases calling for routine HCV testing in gay men who are currently on PrEP. The two men were among 485 HIV-negative gay men receiving PrEP at the clinic between 2011 and 2014.

Published
26 February 2015
From
The Body
Clinicians report two acute HCV infections in Kaiser San Francisco PrEP programme

Two HIV-negative gay men receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only

Published
22 February 2015
By
Liz Highleyman
Cost-Effectiveness of Immediate Hepatitis C Treatment in Early Disease Analyzed

For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in Hepatology.

Published
20 February 2015
From
HCP Live

Filter by country